- Home
- /
- Drugs
- /
- C
- /
- Cisatracurium besylate
- /
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Zydus Lifesciences Limited
Cisatracurium besylate
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Zydus Lifesciences Limited
- Cisatracurium Besylate CISATRACURIUM BESYLATE 2 mg/mL Piramal Healthcare UK Limited
- Cisatracurium Besylate CISATRACURIUM BESYLATE 2 mg/mL Hikma Pharmaceuticals USA Inc.
- Nimbex CISATRACURIUM BESYLATE 2 mg/mL AbbVie Inc.
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Zydus Pharmaceuticals USA Inc.
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Zydus Lifesciences Limited
- Nimbex CISATRACURIUM BESYLATE 2 mg/mL AbbVie Inc.
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Zydus Pharmaceuticals USA Inc.
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Sandoz Inc
- Cisatracurium Besylate CISATRACURIUM BESYLATE 2 mg/mL Hikma Pharmaceuticals USA Inc.
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Caplin Steriles Limited
- Cisatracurium Besylate CISATRACURIUM BESYLATE 2 mg/mL Somerset Therapeutics, LLC
- Cisatracurium Besylate CISATRACURIUM BESYLATE 2 mg/mL Piramal Healthcare UK Limited
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Civica, Inc.
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Caplin Steriles Limited
- Cisatracurium besylate CISATRACURIUM BESYLATE 2 mg/mL Sandoz Inc
- Cisatracurium Besylate CISATRACURIUM BESYLATE 2 mg/mL Somerset Therapeutics, LLC
Summary of product characteristics
Effective Time
20221105
Version
3
Spl Product Data Elements
cisatracurium besylate cisatracurium besylate CISATRACURIUM BESYLATE CISATRACURIUM BENZENESULFONIC ACID WATER cisatracurium besylate cisatracurium besylate CISATRACURIUM BESYLATE CISATRACURIUM BENZENESULFONIC ACID WATER
Application Number
ANDA212171
Brand Name
Cisatracurium besylate
Generic Name
cisatracurium besylate
Product Ndc
72785-0008
Product Type
HUMAN PRESCRIPTION DRUG
Route
INTRAVENOUS
Package Label Principal Display Panel
Principal Display Panel – Container Label (10 mg/5 mL) NDC 72785-0008-1 Cisatracurium Besylate Injection, USP 10 mg/5 mL* (2 mg/mL) WARNING: Paralyzing Agent For Intravenous Injection Preservative free 5 mL Single-Dose Vial Rx only Zydus Pharmaceuticals Principal Display Panel – Container Label (200 mg/20 mL) NDC 72785-0009-1 Cisatracurium Besylate Injection, USP 200 mg/20 mL* (10 mg/mL) WARNING: Paralyzing Agent For ICU use only. For Intravenous Injection Preservative free 20 mL Single-Dose Vial Rx only Zydus Pharmaceuticals Principal Display Panel – Carton Label (10 mg/5 mL) NDC 72785-0008-6 Cisatracurium Besylate Injection, USP 10 mg/5 mL* (2 mg/mL) WARNING: Paralyzing Agent For Intravenous Injection Preservative free 10 x 5 mL Single-Dose Vials Rx only Zydus Pharmaceuticals Principal Display Panel – Carton Label (200 mg/20 mL) NDC 72785-0009-6 Cisatracurium Besylate Injection, USP 200 mg/20 mL* (10 mg/mL) WARNING: Paralyzing Agent For ICU use only. For Intravenous Injection Preservative free 10 x 20 mL Single-Dose Vials Rx only Zydus Pharmaceuticals image10 image11 image12 image13
Drug section
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.